Hawaii Senate Health Committee hears testimony on a bill on prescription drug price transparency Sydney Kurle | Feb 15, 2021
Share this:
The Hawaii Senate Health Committee heard testimony on SB 605 on Wednesday. This bill, titled “Relating to Prescription Drugs
,” received supportive testimony from the American Association of Retired Persons (AARP) Hawaii and the Hawaii Primary Care Association (HPCA). The Pharmaceutical Research and Manufacturers of America (PhRMA) testified in opposition to the bill.
Senate Bill 605 would require drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a 16% or more price increase over a two year period. The bill would also require the manufacturers to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost (WAC) increases by a certain amount during a spe